除了抑制之外:针对CDK9的异位生物功能分子的最新进展
Junzhe Yin1,2, Na Zhang3, Tian Wang4
1Drug Discovery & Development Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Journal of medicinal chemistry
|October 25, 2025
概括
使用PROTACs向蛋白质降解提供了一种新方法来对抗由CDK9.9驱动的癌症. 这些先进的疗法克服药物耐药性,并显示出治疗转录成癌症的前景.
科学领域:
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
- 药物发现 药物发现 药物发现
背景情况:
- 循环素依赖性激酶9 (CDK9) 对于调节癌症相关基因至关重要,使其成为关键的治疗标.
- 现有的CDK9抑制剂在临床使用中面临挑战,包括有限的有效性和耐药性.
- 有针对性的蛋白质降解 (TPD) 提出了一种新的策略来克服这些局限性.
研究的目的:
- 探索TPD策略的潜力,特别是向蛋白质溶解的嵌合体 (PROTACs),以向CDK9.
- 调查 PROTACs 如何诱导 CDK9 无化和降解以获得持续的抗瘤效应.
- 通过多种机制评估创新的异构功能分子以向CDK9.
主要方法:
- 设计用于诱导CDK9降解的PROTACs的开发和应用.
- 对向CDK9.9的异性双功能分子的研究.
- 在癌症模型中评估临床前疗效和耐药性机制.
主要成果:
- PROTACs在对抗CDK9依赖性癌症方面表现出强大且持续的抗瘤活性.
- TPD策略有效地克服了阻力机制,例如MYC上调.
- 对多种分子模式的探索扩大了CDK9.9的治疗向选择.
结论:
- 有针对性的蛋白质降解,特别是PROTACs,为克服传统CDK9抑制剂的局限性提供了一个有希望的方法.
- 这些先进的策略有可能为治疗转录成癌症的新时代带来潜力.
- 针对CDK9的异构功能分子的进一步开发可以显著推进癌症治疗.
相关概念视频
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
M-Cdk Drives Transition Into Mitosis
6.2K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.2K
Positive Regulator Molecules
6.5K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.5K
Positive Regulator Molecules
134.1K
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
134.1K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Anaphase Promoting Complex
3.3K
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.3K


